With big pharma concentrating on Biotechnology this month, February saw no grand gestures in the Pharmaceutical M&A market. Impax Laboratories (NASDAQ: IPXL) acquired the U.S. rights to AstraZeneca’s (NYSE: AZN) migraine headache drug, Zomig. It is sold as a...
Brought to you by www.DealSearchOnline.com April 23, 2012 Issue: Recent Health Care M&A Deals First Quarter M&A Results– 2011 Saw A total of 249 Deals Worth $34.0 Billion Spotlight on: Biotechnology Conference Calendar Recent Health Care...
Brought to you by www.DealSearchOnline.com April 16, 2012 Issue: Recent Health Care M&A Deals Valuing Hospitals Today– 2011 Saw Upward Pressure On Acquisition Multiples Spotlight on: Venture Capital Conference Calendar Recent Health Care M&A...
In the largest deal of the month, one so large that it accounts for slightly more than one-half of all dollars spent on health care M&A, Gilead Sciences (NASDAQ: GILD) is buying Pharmasset, Inc. (NASDAQ: VRUS) for $11.0 billion. Based in Foster City, California,...
2011 Saw Upward Pressure On Acquisition Multiples During 2011, we saw some upward pressure on the acquisition multiples for hospitals due to competition and a market that expanded over the past four years. The results are reported in Irving Levin’s The Health Care...
Warp Drive Bio, a start-up biotech focused on drug development from studying microbes and based in Cambridge, Massachusetts, got itself beamed up $125.0 million in financing. The investor syndicate includes Sanofi (NYSE: SNY) along with founding backer Third Rock...